Treating migraine in pregnancy can be challenging since many drugs carry risks. The good news is that the FDA updated precautions on a drug-free wearable device. Molly O'Brien has the story in this Migraine Minute News Update.

Read More: http://bit.ly/4mMtfo1

Script:

The FDA recently updated its precautionary language on the Nerivio neuromodulation device… removing the note that it has not been studied for use during pregnancy.

Based on a 2023 study published in Headache, the FDA changed the precaution to: "Users should consult their healthcare provider if they are pregnant or intend to get pregnant prior to using the device."

As we previously reported in an August 2023 Migraine Minute News update, the study's results suggest that the Nerivio device is a safe treatment for migraine during pregnancy, does not increase the risk for adverse pregnancy outcomes, and may offer a drug-free treatment option for migraine during pregnancy.

First-of-its-kind study: A new study suggests that a combination of THC + CBD works better than placebo, THC alone, or CBD alone for reducing migraine pain and symptoms. Molly O'Brien breaks it down in this Migraine Minute News Update.

Read More: https://bit.ly/4qvpuWo

A recent study found that when treating migraine attacks, a vaporized combination of THC and CBD worked better than THC alone, CBD alone, or a placebo. THC alone helped with pain, but not other symptoms, while CBD alone did not show any benefit.

Study participants who used the THC/CBD combination also saw improvements in light and sound sensitivity, but not nausea or vomiting.

No serious adverse events were reported.

In an interview with MedScape, one researcher noted that people experienced benefits without using higher, recreational doses of cannabis.

A new real-world study shows atogepant (sold under brand name Qulipta) may quickly reduce migraine days—even for those who haven't responded to other treatments. Molly O'Brien has more in this Migraine Minute News Update!

Read more: http://bit.ly/3UcEuJN
CC License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Script:
The GIANT study, published inThe Journal of Headache and Pain, offers real-world evidence that atogepant is a safe, well-tolerated, and effective for migraine prevention—among those whose prior treatments didn't work.

Researchers looked at the impact of 60 mg of atogepant, taken once daily in people with either high-frequency episodic or chronic migraine. Many of the participants had already tried at least three other preventive treatments… including CGRP monoclonal antibodies.

Results? At 12 weeks, on average, participants saw a decrease of 6 migraine days and 11 headache days per month. In fact, nearly 60% of experienced at least a 50 percent drop in migraine days. Pain intensity, disability, and use of acute drugs also dropped.

Some saw improvement in migraine frequency within the first week.